Does Medicare Cover Semaglutide for Weight Loss?

For the first time, sometimes yes. As of July 1, 2026, Medicare covers certain GLP-1 medications for weight management — including Wegovy® (semaglutide) — for eligible beneficiaries through a temporary program called the Medicare GLP-1 Bridge, at a $50 copayment for a one-month supply.^[1] That reverses a two-decade default in which a prescription written purely for weight loss sat outside what Medicare drug plans could pay for. The program is real, and it is temporary — CMS describes it as a short-term demonstration running through December 31, 2027^[2] — and its rules are specific. Here's the honest map: what changed, who qualifies, and where transparent self-pay fits if Medicare's answer for you is still no.

What changed on July 1, 2026

Medicare's coverage page now states it plainly: "Starting July 1, 2026, Medicare covers these GLP-1 drugs" — Foundayo®, Wegovy®, and Zepbound® — each covered only in the specific product forms medicare.gov lists.^[1] The vehicle is the Medicare GLP-1 Bridge, which CMS describes as a short-term demonstration that operates outside the regular Part D benefit, running from July 1, 2026 through December 31, 2027.^[2]

The cost is a $50 copayment at the pharmacy for a one-month supply, regardless of income level.^[3] Because the Bridge sits outside your regular drug coverage, medicare.gov notes the $50 doesn't count toward your Part D deductible or out-of-pocket limit and can't be reduced through programs like Extra Help.^[1]

Who qualifies — per medicare.gov, as of this update

You must have Medicare drug coverage (Part D) — a standalone drug plan or a Medicare Advantage plan that includes drug coverage — be 18 or older, and meet one of three BMI-based bars: a BMI of 35 or more; a BMI of 30–34.99 plus at least one listed condition (diastolic heart failure, uncontrolled high blood pressure, chronic kidney disease at stage 3a or higher, prediabetes, a previous heart attack or stroke, or symptomatic peripheral artery disease); or a BMI of 27–29.99 plus prediabetes, a previous heart attack or stroke, or symptomatic peripheral artery disease.^[1]

Your prescriber sends the prescription and, when requested, completes a prior authorization certifying the GLP-1 is part of a lifestyle program focused on diet and exercise; once granted, it stays valid through December 31, 2027, unless you change GLP-1s (medicare.gov covers how refills carry over).^[1]

Excluded by design: people already getting a GLP-1 paid for by their Medicare drug plan, and people with certain other diagnoses — type 2 diabetes is the leading example — because for those, medicare.gov says, a Part D plan itself might already cover a GLP-1.^[1]

The coverage paths that existed before still exist

The background matters, because the Bridge is temporary. The Part D benefit was written to carve out drug categories a plan may not cover, by reference to a statute listing "agents when used for anorexia, weight loss, or weight gain,"^[4] and CMS's Part D excluded-drugs guidance confirms those agents may not be covered under the basic Part D benefit.^[5] That statutory exclusion is why this article's title question drew a flat no for so long.

It's also why the older path still works: the same CMS guidance provides that Part D drugs can be covered when used for a "medically accepted indication."^[5] Ozempic®, when prescribed for type 2 diabetes, is the everyday example. Whether that path applies to you depends on your diagnoses, your prescriber's judgment, and your plan's formulary — each plan keeps its own list of covered drugs.^[6]

How to run your own coverage check (15 minutes, worth it)

1. Start with the Bridge: medicare.gov's "Weight loss drugs" page has an eligibility walkthrough, and 1-800-MEDICARE can answer eligibility and prior-authorization questions.^[1]

2. For the Part D path, pull your plan's current formulary and search the specific brand names — Wegovy®, Ozempic® — not just "semaglutide."

3. Ask your plan specifically: covered for which diagnosis, at which tier, with what prior authorization?

4. Talk with your prescriber about whether a covered, on-label path fits your medical situation — that's their call to make, not a workaround to request.

Where self-pay fits now

Straight talk: if you meet the Bridge criteria, $50 for a one-month supply of a branded, FDA-approved medication is the number to beat — check that door before paying cash anywhere, including here.

But the rules leave real gaps — no Medicare drug coverage, a BMI below the program's bars or without a qualifying condition — and the program is currently scheduled to end December 31, 2027.^[2] For people outside those lines, self-pay remains the realistic path. Ladies First is 100% self-pay by design — no insurance, no prior authorizations, no coverage roulette. Pricing is flat and published:

• Compounded semaglutide — from $219 per 28 days of medication on a 12-week plan, or $249 per 28 days on a flexible plan
• Compounded tirzepatide — from $309 per 28 days on a 12-week plan, or $339 flexible
• Oral semaglutide — from $259 per 28 days on a 12-week plan, or $279 flexible

Every plan includes provider visits, dose adjustments (with no price change as your dose steps up), 1:1 coaching, and shipping — billed per cycle, cancel any time, and you're never charged unless a provider approves your plan. One distinction matters enough to state plainly. Compounded medications are not FDA-approved. They are prepared in FDA-regulated facilities.^[7] The Bridge's covered list is specific branded products,^[1] and brand-name, FDA-approved medications are also available through your provider at their correspondingly higher self-pay prices. Which option is medically appropriate for you is your provider's determination during intake.

The bottom line

As of July 2026, Medicare does cover GLP-1 weight-loss medication for eligible beneficiaries — Wegovy® under the temporary GLP-1 Bridge, at a $50 copayment^[1] — and coverage for other uses — type 2 diabetes treatment above all — still runs plan-by-plan through Part D formularies.^[5] The program is rule-bound and currently scheduled to sunset at the end of 2027,^[2] so check your own eligibility rather than assuming either way. If Medicare's answer for you is no — or the timeline runs out — transparent, flat self-pay care exists.

See what self-pay care actually costs for you. Answer a few health questions online — about 3 minutes, free — and a medical provider licensed in your state reviews your health history, usually within 48 hours. Flat published pricing, cancel any time — and you're never charged unless a provider approves your plan.